Document is current
Any future updates will be listed below
-
Authors
van der Leest, Paul https://orcid.org/0000-0001-8527-4956
Rozendal, Pim
Rifaela, Naomi
van der Wekken, Anthonie J. https://orcid.org/0000-0001-7175-0026
Kievit, Hanneke
de Jager, Vincent D. https://orcid.org/0009-0009-3539-8809
Sidorenkov, Grigory
van Kempen, Léon C.
Hiltermann, T. Jeroen N. https://orcid.org/0000-0002-0665-2160
Schuuring, Ed https://orcid.org/0000-0003-3655-143X
-
Funding
Funding for this research was provided by:
Agena Bioscience
- License Information
-
More Information
Article History
Received: 5 April 2024
Accepted: 8 May 2025
First Online: 28 May 2025
Competing interests
: The authors declare the following competing interests: Anthonie J. van der Wekken has a leadership role in the oncology section of NVALT, the guideline committee NSCLC and CUP, and the dure geneesmiddelen committee of NVALT and FMS; is a consultant on advisory boards for AstraZeneca, Eli Lilly, Janssen-Cilag, Roche, and Takeda; has performed lectures for AstraZeneca, BMS, Eli Lilly, Pfizer, and Roche; and has received research grants form AstraZeneca, Boehringer-Ingelheim, and Pfizer. Léon C. van Kempen has a leadership role in the EORTC Melanoma Group and the Commission Personalized Medicine – Belgium; is a consultant on advisory boards for Cyclomics, Janssen-Cilag, LOGEX, Merck Serono, Protyon, and Roche; and has received grants and non-financial support from Amgen, AstraZeneca, Bayer, BMS, Eli Lilly, Janssen-Cilag, LOGEX, Lynxcare, Merck Serono, nanoString, Novartis, Pfizer, and Roche. T. Jeroen N. Hiltermann has a leadership role in the CieBOM; is a consultant on advisory boards for BMS, MSD, Pfizer, and Roche; has received research grants from AstraZeneca, BMS, and Roche; and is involved in clinical studies in collaboration with Amgen, AstraZeneca, BMS, GSK, Merck Serono, Novartis, and Roche. Ed Schuuring has a leadership role in the Dutch Society of Pathology, the European Society of Pathology, the European Liquid Biopsy Society, the CieBOD, and the national guideline committee; is a consultant on advisory boards for Agena Bioscience, Amgen, Astellas Pharma, AstraZeneca, Bayer, BMS, CC Diagnostics, Eli Lilly, GSK, Illumina, Janssen-Cilag, Merck Serono, Novartis, Roche, SinnoVision Lab, and Sysmex; has performed lectures for Agena Bioscience, Biocartis, Bio-Rad, Eli Lilly, Illumina, Roche, and SeraCare Life Sciences; and has received grants and non-financial support from Abbott, Agena Bioscience, ArcherDX, AstraZeneca, Bayer, Biocartis, Bio-Rad, Boehringer Ingelheim, CC Diagnostics, Eli Lilly, Illumina Merck Serono, Roche, and SeraCare Life Sciences. Other authors declare no competing interests.
